Sunshine Biopharma Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Sunshine Biopharma Inc. (SBFM) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $212.41 thousand as of 2025-12-31, per its 10-K filed 2026-04-03.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-04-03
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $212.41K.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $112.71K.
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $105.46K.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $73.26K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-12-31 | $212.41K 10-K · filed 2026-04-03 |
| 2024-12-31 | $112.71K 10-K · filed 2025-04-01 |
| 2024-09-30 | $105.46K 10-Q · filed 2024-11-05 |
| 2024-06-30 | $73.26K 10-Q/A · filed 2024-08-20 |
| 2024-03-31 | $74.00K 10-Q · filed 2024-05-20 |
| 2023-12-31 | $59.74K 10-K · filed 2024-03-28 |
| 2023-09-30 | $55.42K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $46.81K 10-Q · filed 2023-08-10 |
| 2015-12-31 | $59.63K 10-K · filed 2016-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |